Patients with psoriatic arthritis and axial spondyloarthritis may be able to safely taper tumor necrosis factor inhibitors using a treat-to-target approach, new research indicates.
Patients with psoriatic arthritis and axial spondyloarthritis may be able to safely taper tumor necrosis factor inhibitors using a treat-to-target approach, new research indicates.
Researchers estimated the short-term risks and long-term incidence rates of infection and malignancy with IL-17 or IL-23 inhibitors among patients with psoriasis and psoriatic arthritis.
Researchers estimated the short-term risks and long-term incidence rates of infection and malignancy with IL-17 or IL-23 inhibitors among patients with psoriasis and psoriatic arthritis.
Dr Paudel reviews research she and colleagues conducted to validate the EULAR definition of difficult-to-treat rheumatoid arthritis, and differences among patients with difficult-to-treat RA versus those with controlled disease.
Dr Paudel reviews research she and colleagues conducted to validate the EULAR definition of difficult-to-treat rheumatoid arthritis, and differences among patients with difficult-to-treat RA versus those with controlled disease.
